We are live on ! Find out more
BSX icon

Boston Scientific

43.34 USD
-0.21
0.48%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
43.47
+0.13
0.3%
1 day
-0.48%
5 days
-1.5%
1 month
-14.13%
3 months
-4.31%
6 months
-39.2%
Year to date
-54.24%
1 year
-55.88%
5 years
-0.69%
10 years
84.35%
 

About: Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.

Employees: 59,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 30.1%
Neutral 26%
Negative 43.8%
Positive
Zacks Investment Research
1 day ago
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.
BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
Negative
Zacks Investment Research
2 days ago
New Strong Sell Stocks for September 16th
AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.
New Strong Sell Stocks for September 16th
Positive
Seeking Alpha
3 days ago
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)
Boston Scientific is upgraded to 'Strong Buy' as market overreaction creates an attractive entry point for long-term investors. BSX trades at a forward P/E of 13.1, well below its historical average, despite robust profitability and solid Q2 2026 results. Growth headwinds from WATCHMAN and electrophysiology are offset by strong Interventional Cardiology and Vascular Therapies momentum.
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade)
Positive
Zacks Investment Research
4 days ago
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
Negative
Seeking Alpha
7 days ago
Boston Scientific: $43 Finally Prices In A Bad 2026
Boston Scientific's cyberattack will hurt third-quarter results, but manufacturing and shipping recovered quickly enough that much of the missing revenue should be delayed rather than lost. I am more concerned about WATCHMAN and U.S. electrophysiology, which had already slowed before the attack, and the additional debt coming with Penumbra. BSX shares now trade near 13 times the company's withdrawn earnings forecast. I estimate fair value at $55, leaving enough room for a Buy without assuming that growth immediately returns.
Boston Scientific: $43 Finally Prices In A Bad 2026
Positive
Zacks Investment Research
7 days ago
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Neutral
Zacks Investment Research
8 days ago
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
Neutral
Seeking Alpha
8 days ago
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positive
WSJ
8 days ago
Boston Scientific Restores Key Operations After Cyberattack
The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.
Boston Scientific Restores Key Operations After Cyberattack
Negative
Benzinga
10 days ago
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.
Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
Price charts implemented using Lightweight Charts™